Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™…
No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for potential launch of YUTREPIA between end of…